Published Research and Presentations

89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP) – A phase I trial of a novel staging modality for urothelial carcinoma

Other

EAU26

16/03/2026

Dickon Hayne, Richard Gauci, Pravin Viswambaram, Teng Hoo, Kevin G Keane, Steve P McCombie, Samantha R Oakes, Elizabeth Liow, Jayne Lim, Cynthia Hawks, Nat Lenzo, Thomas Ferguson, Katie Meehan, Andrew Redfern

BCG plus mitomycin (BCG+MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC): effects on urinary symptoms and other aspects of health-related quality of life (HRQL) in a randomised trial (BCGMM, ANZUP 1301)

BCG+MM

EAU26

15/03/2026

Prof Dickon Hayne

Gemcitabine-Docetaxel Intravesical Synchronous CO-administration A phase I study: G-DISCO (ANZUP 2403)

Other

EAU26

15/03/2026

Keane K.G., Hawks C., McCombie S., Oh E.L., Twycross M., Lim J., Redfern A., Hayne D., UWA Medical School, University of Western Australia, South Metropolitan Health Service, Murdoch, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group

Addition of Early Docetaxel to Enzalutamide for Metastatic Hormone-Sensitive Prostate Cancer: A Trial Emulation Approach based on the ENZAMET (ANZUP 1304) trial

ENZAMET

ESMO 2025

19/10/2025

Yu Yang Soon, Ian Marschner, I. Manjula Schou, Christopher J. Sweeney, Ian D. Davis, Martin Stockler, Andrew Martin

PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): a randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)

TheraP

ESMO 2025

19/10/2025

Tahlia Scheinberg, Rhiannon Mellor, Arun A Azad, Paul Bonnitcha, James Buteau, Ian D Davis, Louise Emmett, Michael Fitzpatrick, Roslyn J Francis, Rachel MN Kim, Edmond Kwan, Hui-Ming Lin, Andrew J Martin, Peter J Meikle, Andrew M Scott, Martin Stockler, Alexander W Wyatt, Michael S Hofman, Lisa G Horvath for the TheraP trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

#2483P: PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304)

ENZAMET

ESMO 2025

19/10/2025

Rhiannon Mellor, Michael Fitzpatrick, Tahlia Scheinberg, Rachel MN Kim, Paul Bonnitcha, David Sullivan, Hui-Ming Lin, Ian D Davis, Andrew J Martin, Peter J Meikle, Anthony Joshua, Margaret McJannett, Vinod Subhash, Sonia Yip, Scott A North, Raymond S McDermott, Kim N. Chi, Martin R Stockler, Christopher Sweeney, Lisa G Horvath for the ENZAMET trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Circulating tumour cell (CTC) characteristics associated with survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) in a randomised trial of enzalutamide with or without [177Lu]Lu-PSMA-617 (ENZA-p; ANZUP 1901)

ENZA-p

ESMO 2025

19/10/2025

Megan Crumbaker, Santosh Gupta, Nathan Papa, Nadine Hartmann, Rick Wenstrup, Shahneen Sandhu, Anthony M. Joshua, Shalini Subramaniam, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C. Goh, Sonia Yip, Vinod Subhash, Hayley Thomas, Michael S Hofman, Martin R Stockler, Ian D Davis, Louise Emmett, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502)

PCR MIB

ASCO 2025

03/06/2025

A. Weickhardt, F. Foroudi, N. Lawrentschuk, J. Xie, Y. Ko, M. Sidhom, A. Pal, P. Grimison, A. Zhang, S. Ng, C. Tang, E. Hovey, C. Chen, G. Hruby, A. Guminski, S.R.Oakes, C. Conduit, B. Tran, I.D Davis, D.Hayne on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304)

ENZAMET

ASCO 2025

03/06/2025

Lisa G Horvath, Hui-Ming Lin, Ian D Davis, Andrew J Martin, Nicole Yeung, Rachel MN Kim, Neil Portman, Anthony Joshua, Margaret McJannett, Vinod Subhash, Sonia Yip, Scott A North, Raymond S McDermott, Kim N Chi, Martin R Stockler, Christopher Sweeney for the ENZAMET trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Prognostic value of PSMA-PET against CHAARTED criteria in an ENZAMET sub-cohort

ENZAMET

ASCO 2025

03/06/2025

Z Sabahi, N Papa, W P. Fendler, A Nguyen, K Wong, N Ayati, B Ho, J Chen, T Cusick, I A. Burger, M Crumbaker, G Marx, S Sharma, M Frydenberg, S Sandhu, I D. Davis, M R. Stockler, C Sweeney, A M. Joshua, L Emmett, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)